DiagnoCure announces the filing of a preliminary prospectus



    
    /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
    DISSEMINATION IN THE UNITED STATES/

    Ticker Symbol: CUR
    

    QUEBEC CITY, June 25 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR)
("Diagnocure" or the "Company"), a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services,
announced today that it has filed a preliminary short form prospectus with the
securities authorities in ail provinces of Canada with respect to a proposed
offering of its common shares.
    The offering is being made on a best efforts basis through a syndicate of
agents co-led by National Bank Financial Inc. and Bloom Burton & Co. and
including Desjardins Securities Inc.
    The Company has filed a request for an advance income tax ruling from the
Ministère du Revenu du Québec to confirm that the Company qualifies as a
qualified issuing corporation and that the common shares to be distributed
under this offering will qualify as qualifying shares, upon issuance, for
inclusion in a Québec Stock Savings Plan II (formerly known as SME Growth
Stock Plan) in accordance with the Taxation Act (Québec).
    The Company intends to use the net proceeds of this offering primarily to
advance its research and development initiatives, including key clinical
studies to further demonstrate the clinical value of its Previstage(TM) GCC
Colorectal Cancer test and support its commercialization. The Company intends
also to allocate a portion of the proceeds of the offering for the development
of its GCC Blood test for monitoring colorectal cancer and to pursue further
studies and research and development activities on the Shc protein-based
tests.
    Copies of the preliminary short form prospectus relating to this offering
of common shares may be obtained from the agents or through the SEDAR internet
site (www.sedar.com).
    The securities offered have not and will not be registered under the
United States Securities Act of 1933, as amended (the "U.S. Securities Act"),
or any U.S. State securities laws and may not be offered or sold, directly or
indirectly, within the United States or its territories or possessions or to
or for the account of any U.S. person (as defined in Regulation S under the
U.S. Securities Act) other than pursuant to an available exemption from the
registration requirements of the U.S. Securities Act. This press release does
not constitute an offer to sell or a solicitation of an offer to buy any such
securities within the United States, or its territories or possessions, or to
or for the account of any U.S. person.
    This offering is expected to close on or around July 15, 2009 and is
subject to usual conditions.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc,
launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the
first GCC-based molecular test for the management of colorectal cancer. A
major study published in the February 18, 2009, edition of the Journal of the
American Medical Association demonstrated that GCC, to which DiagnoCure owns
exclusive worldwide diagnostic rights, is the strongest independent predictor
of colorectal cancer recurrence. The Company also has a strategic alliance
with Gen-Probe (NASDAQ:   GPRO) for the development and commercialization of a
second-generation prostate cancer test using PCA3, DiagnoCure's proprietary
molecular marker. This test is also available through laboratories in the U.S.
using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the
CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. For more
information, visit www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein unless required by the applicable
securities laws and regulations.
    %SEDAR: 00003671EF




For further information:

For further information: Investors: Jean-François Bureau, CFA, Sr. Vice
President and CFO, DiagnoCure Inc., (418) 527-6100,
communications@diagnocure.com; Media: Paule De Blois, Vice President,
Corporate Affairs, DiagnoCure Inc., (418) 527-6100, p.deblois@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890